Haihong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haihong Wang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Buze Chen
Xuzhou Medical University, Xuzhou, China
1 shared publication - Che Jinhui
The Department of Hepatopancreatobillary Surgery, Xuzhou City Cancer Hospital, Xuzhou, Jiangsu 221005,China
1 shared publication - Chunyan Cao
Department of Neurosurgery, affiliated Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Dongping Xie
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
1 shared publication - Guilin Li
Key Laboratory of Precision Nutrition and Food Quality, Ministry of Education, Department of Nutrition and Health, College of Biological Sciences, China Agricultural University, Beijing, China
1 shared publication - Haifeng Jiang
Nanjing University of Science and Technology School of Automation
1 shared publication
Latest Publications
- Open Access
- 15 February 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 831276
A Case Report of Excessive Use of Clozapine Combined With Clonazepam
Introduction: For patients with schizophrenia, clozapine (CLZ) in combination with clonazepam (CLNAZ) is one of the viable therapeutic options. We successfully reduced the doses of CLZ and CLNAZ to the safe range of a polydrug abuse patient. As far as we know, this is the first case of this problem. As there are no relevant guidelines to reduce CLZ or CLNAZ, we hope to share this case to provide a reference for the prevention and treatment of similar patients with multidrug abuse. Case Presentation: This case report describes a 46-year-old male with a 24-year history of schizophrenia. His main clinical manifestations are auditory hallucinations, persecutory delusion, and emotional instability. In 2012, the patient started taking rifampicin due to tuberculosis and gradually overused CLZ and CLNAZ. Before admission, he took 1,275 mg of CLZ every day and 26 mg of CLNAZ every night. With the help of Therapeutic Drug Monitoring (TDM) and pharmacogenetic testing, we gradually reduced his daily dose of CLZ and CLNAZ and formulated a more reasonable dosing schedule for him. At the time of discharge, the patient took CLZ 450 mg per day and CLNAZ 2 mg per night, with no obvious symptoms of psychosis. Conclusion: In the process of drug maintenance treatment of schizophrenia, it is necessary to adopt TDM strategy to reduce and treat the abuse of multiple prescription drugs.
- 15 February 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 831276
Open AccessA Case Report of Excessive Use of Clozapine Combined With Clonazepam
Introduction: For patients with schizophrenia, clozapine (CLZ) in combination with clonazepam (CLNAZ) is one of the viable therapeutic options. We successfully reduced the doses of CLZ and CLNAZ to the safe range of a polydrug abuse patient. As far as we know, this is the first case of this problem. As there are no relevant guidelines to reduce CLZ or CLNAZ, we hope to share this case to provide a reference for the prevention and treatment of similar patients with multidrug abuse. Case Presentation: This case report describes a 46-year-old male with a 24-year history of schizophrenia. His main clinical manifestations are auditory hallucinations, persecutory delusion, and emotional instability. In 2012, the patient started taking rifampicin due to tuberculosis and gradually overused CLZ and CLNAZ. Before admission, he took 1,275 mg of CLZ every day and 26 mg of CLNAZ every night. With the help of Therapeutic Drug Monitoring (TDM) and pharmacogenetic testing, we gradually reduced his daily dose of CLZ and CLNAZ and formulated a more reasonable dosing schedule for him. At the time of discharge, the patient took CLZ 450 mg per day and CLNAZ 2 mg per night, with no obvious symptoms of psychosis. Conclusion: In the process of drug maintenance treatment of schizophrenia, it is necessary to adopt TDM strategy to reduce and treat the abuse of multiple prescription drugs.
- Open Access
- 1 July 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 3707-3717
Bioinformatics Analysis of KIF1A Expression and Gene Regulation Network in Ovarian Carcinoma
Background: The study aims to analyze the expression levels of kinesin family member 1A (KIF1A) in ovarian cancer (OC) and explore its clinical significance in the development of OC and its potential regulatory network. Methods: The Cancer Genome Atlas (TCGA) OC data was used to examine the expression differences between OC and normal tissue and explore the correlation with tumor stage. The relationship between KIF1A expression and prognosis was analyzed using Oncomine and Kaplan–Meier plotter tools. The co-expression network of KIF1A in TCGA OC was analyzed based on the application of cBioPortal, GO cluster, and KEGG analyses were performed based on the co-expression network. Immune-infiltration analysis were used to analyze the significant involvement of KIF1A in function. Results: KIF1A was highly elevated in OC tissues and KIF1A expression was significantly correlated with the FIGO stage (P=0.015) and age (P=0.020). High KIF1A expression of OC predicted the poor prognosis including overall survival (OS) (HR: 1.27; 95% CI: 1.11– 1.45; P=0.00046) and post-progression survival (PFS) (HR: 1.18; 95% CI: 1.03– 1.35; P=0.015). GO and KEGG analysis showed KIF1A had a potential role in the biological process of ATP-dependent chromatin remodeling, transcription, DNA-templated cytolysis, positive regulation of T cell proliferation, positive regulation of transcription, DNA-templated via cell adhesion molecules (CAMs), primary immunodeficiency, oxidative phosphorylation, NF-kappa B signaling pathway, pathways in cancer and Wnt signaling pathway, and immune infiltrating cells. Conclusion: KIF1A was highly expressed and correlated with poor survival and immune infiltration in OC, and it may be a prognostic biomarker in OC.
- 1 July 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 3707-3717
Open AccessBioinformatics Analysis of KIF1A Expression and Gene Regulation Network in Ovarian Carcinoma
Background: The study aims to analyze the expression levels of kinesin family member 1A (KIF1A) in ovarian cancer (OC) and explore its clinical significance in the development of OC and its potential regulatory network. Methods: The Cancer Genome Atlas (TCGA) OC data was used to examine the expression differences between OC and normal tissue and explore the correlation with tumor stage. The relationship between KIF1A expression and prognosis was analyzed using Oncomine and Kaplan–Meier plotter tools. The co-expression network of KIF1A in TCGA OC was analyzed based on the application of cBioPortal, GO cluster, and KEGG analyses were performed based on the co-expression network. Immune-infiltration analysis were used to analyze the significant involvement of KIF1A in function. Results: KIF1A was highly elevated in OC tissues and KIF1A expression was significantly correlated with the FIGO stage (P=0.015) and age (P=0.020). High KIF1A expression of OC predicted the poor prognosis including overall survival (OS) (HR: 1.27; 95% CI: 1.11– 1.45; P=0.00046) and post-progression survival (PFS) (HR: 1.18; 95% CI: 1.03– 1.35; P=0.015). GO and KEGG analysis showed KIF1A had a potential role in the biological process of ATP-dependent chromatin remodeling, transcription, DNA-templated cytolysis, positive regulation of T cell proliferation, positive regulation of transcription, DNA-templated via cell adhesion molecules (CAMs), primary immunodeficiency, oxidative phosphorylation, NF-kappa B signaling pathway, pathways in cancer and Wnt signaling pathway, and immune infiltrating cells. Conclusion: KIF1A was highly expressed and correlated with poor survival and immune infiltration in OC, and it may be a prognostic biomarker in OC.
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (8) , 1106-1113
Mir-320b Inhibits Pancreatic Cancer Cell Proliferation by Targeting FOXM1
Backround: Pancreatic ductal adenocarcinoma (PDAC) is the most common and deadly cancer. Surgical resection is the only possible cure for pancreatic cancer but often has a poor prognosis, and the role of adjuvant therapy is urgently explored.Methods: MicroRNAs (miRNAs) play very important role in tumorigenesis by regulating the target genes. In this study, we identified miR-320b lower-expressed in human pancreatic cancer tissues but relatively higher-expressed in the adjacent nontumor tissues.Results: Consistently,the expression of miR-320b in different pancreatic cancer cell lines was significantly lower than the normal pancreatic cells. In order to identify the effects of miR-320b on cell growth, we overexpressed miR-320b in PANC-1 and FG pancreatic cancer cell lines, CCK8 and BrdU incorporation assay results showed that miR-320b inhibited cell proliferation.Discussion: We next predicted miR-20b targeted FOXM1(Forkhead box protein M1)and identified the negative relationship between miR-320b and FOXM1.We also demonstrated that elevated miR-320b expression inhibited tumor growth in vivo.Conclusion: All of these results showed that miR-320b suppressed pancreatic cancer cells proliferation by targeting FOXM1, which might provide a new diagnostic marker for pancreatic cancer.
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (8) , 1106-1113
Mir-320b Inhibits Pancreatic Cancer Cell Proliferation by Targeting FOXM1
Backround: Pancreatic ductal adenocarcinoma (PDAC) is the most common and deadly cancer. Surgical resection is the only possible cure for pancreatic cancer but often has a poor prognosis, and the role of adjuvant therapy is urgently explored.Methods: MicroRNAs (miRNAs) play very important role in tumorigenesis by regulating the target genes. In this study, we identified miR-320b lower-expressed in human pancreatic cancer tissues but relatively higher-expressed in the adjacent nontumor tissues.Results: Consistently,the expression of miR-320b in different pancreatic cancer cell lines was significantly lower than the normal pancreatic cells. In order to identify the effects of miR-320b on cell growth, we overexpressed miR-320b in PANC-1 and FG pancreatic cancer cell lines, CCK8 and BrdU incorporation assay results showed that miR-320b inhibited cell proliferation.Discussion: We next predicted miR-20b targeted FOXM1(Forkhead box protein M1)and identified the negative relationship between miR-320b and FOXM1.We also demonstrated that elevated miR-320b expression inhibited tumor growth in vivo.Conclusion: All of these results showed that miR-320b suppressed pancreatic cancer cells proliferation by targeting FOXM1, which might provide a new diagnostic marker for pancreatic cancer.
- 1 December 2011
- Published by Elsevier in Regulatory Peptides
- Vol. 172 (1-3) , 30-34
Exogenous oxytocin reverses the decrease of colonic smooth muscle contraction in antenatal maternal hypoxia mice via ganglia
- 1 December 2011
- Published by Elsevier in Regulatory Peptides
- Vol. 172 (1-3) , 30-34
Exogenous oxytocin reverses the decrease of colonic smooth muscle contraction in antenatal maternal hypoxia mice via ganglia